LPAD Approval Pathway Is Not Saving Antimicrobial Development

 
• By Derrick Gingery

US FDA and CMS explore reimbursement ideas to strengthen business case for antimicrobial development; new approval pathway likely is only needed in special situations.

Bundle of money and pack of medication tablets or drug pills, close-up. Expensive health care concept, selective focus

More from Review Pathways

More from Pathways & Standards